Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01672632
Other study ID # PBRC 26040
Secondary ID 5R01DK060412
Status Completed
Phase N/A
First received
Last updated
Start date May 2008
Est. completion date December 2020

Study information

Verified date April 2021
Source Pennington Biomedical Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It has been shown that large fat cells are associated with more risks for insulin resistance and more cardiovascular risk factors such as high cholesterol or triglycerides.


Description:

This study will look at fat cell size and how it affects fat deposition, insulin resistance and muscle oxidative capacity. A comparison will be made with the differences between participants with larger versus smaller fat cells in insulin resistance and blood levels of lipids. The study will also determine if characteristics of fat cells and muscle can predict the development of weight gain-induced insulin resistance.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 2020
Est. primary completion date February 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Your Body Mass Index (height to weight ratio) is 22.5 to 32.5 (inclusive). - You are 18-40 years of age. - You are willing to enroll in an 8 week overfeeding study causing a 5-8 % weight gain. - You are willing to eat all your meals from Pennington and only meals from Pennington for approximately 10 weeks total, even when you are full. Prior to overfeeding 2 Meals per day will be served at Pennington with lunch packed for at least 7 days. After that time participants will receive and eat all (overfeeding) meals at PBRC for 8 weeks. Post-overfeeding will consists of weight-maintenance diet for 1 week. All meals will be monitored at Pennington. - You are willing to maintain the same level of exercise after enrollment in the study throughout the length of the study. - You are willing to complete nutritional and activity questionnaires. Exclusion Criteria: - You weight > 300 lbs - You have a history of cardiovascular disease or diabetes. - You have a fasting blood glucose > 110 mg/dL. - You have an average screening blood pressure > 140/90. - You have liver disease. - You have thyroid disease. - Have Acid Reflux - Had cancer in the last 5 years (Some skin cancers OK) - Have HIV - Have had an Eating Disorders - You are pregnant or breastfeeding. - You have gained or lost more than 3kg in the last 3 months - You require chronic use of medications including diuretics, steroids and adrenergic-stimulating agents. - You or a member of your family has a history of blood clots (deep vein thrombosis or pulmonary embolism) - You have poor circulation, history of bypass operation in your legs, blood coagulation disorders, diagnosed peripheral arterial or vascular disease, cramping pain in your leg muscle during exercise or nerve damage to your legs - You have varicose veins (per discretion of MD or NP) - You have had previous GI surgery, obstructive disease of the GI tract, hyper motility disorder or a history of problems of impairment of the gag reflex. - You have emotional problems such as clinical depression or other diagnosed psychological conditions. - You are claustrophobic. - You have metal objects in your body such as implanted rods or surgical clips or magnetic objects that are incompatible with the MRI/MRS. - You smoke or use tobacco products

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Overfeeding
We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.

Locations

Country Name City State
United States Pennington Biomedical Research Center Baton Rouge Louisiana

Sponsors (2)

Lead Sponsor Collaborator
Pennington Biomedical Research Center National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the effect of 8-weeks 40% high fat overfeeding in 40 healthy, young adults on adipose and skeletal muscle characteristics, ectopic fat accumulation, insulin sensitivity, and metabolic flexibility. This study will investigate how fat cell size (independent of total fat mass) affects metabolic outcomes of overfeeding, including changes in fat deposition, insulin sensitivity and muscle oxidative capacity. It has been shown that large fat cells relative to fat mass are associated with higher risks for insulin resistance and type 2 diabetes. 10 months
Secondary Fat Deposition Viewing of adipose tissue or body fat and skeletal muscle characteristics over a period. 10 Months
Secondary Insulin Sensitivity Measure and monitor the natural hormone insulin becomes less effective at lowering blood sugars. The resulting increase in blood glucose may raise levels outside the normal range and cause adverse heealth effects, depending on dietary conditions or sensitivity of cells to insulin. 10 months
Secondary Muscle Oxidative Capacity A measure of a muscle's maximal capacity to use oxygen in microliters of oxygen consumed per gram of muscle per hour. 10 Months
Secondary Circadian Blood Pressure variability Blood pressure and heart rate measurement: An automatic BP monitoring device (Mortara® Ambulo 2400) for ambulatory use was attached to a BP cuff to obtain blood pressure (BP) and heart rate (HR) readings at 30-min intervals during the day (6:30 AM to 9:30 PM) and 60-min intervals at night (10 PM to 6 AM) while the participants went about their activities. Data were downloaded into the database at the end of the 7-day recording span for a chronobiological analysis. This was done at baseline, post-overfeeding and at 3 months. 10 Months
Secondary Resting Endothelial function testing Endothelial function testing: Assessment of resting endothelial function was done with the participant in a fasting state, after having avoided stimulants (caffeine, tobacco, alcohol, exercise) for 12 hours, at the same fixed clock hour (range 8-10 AM), using the EndoPAT 2000 device manufactured by ITAMAR Medical®. 10 Months